The Society for Clinical Data Management and the Association of Clinical Research Professionals are pleased to announce a new collaboration that will help the organizations improve their support of professionals in clinical research.
“This is a natural relationship that makes sense for the members of both organizations,” said Ralph J. Russo, CCDM, chair of the SCDM Board of Trustees. “By providing events and educational opportunities across organizations, this agreement will foster innovation and synergy in the way data managers and other clinical professionals work together each day.”
Representing a combined 22,500 members worldwide, SCDM and ACRP share a common interest in promoting excellence among the various roles in clinical research. Collaborative efforts may include jointly-sponsored education programs, publication of best practices and cross-promotion of meetings and events.
“We are extremely excited to combine our efforts with SCDM,” said James D. Thomasell, CPA, ACRP executive director. “Our organizations are a natural fit both in terms of our missions and culture. We look forward to working closely with SCDM in advancing our missions and benefiting the clinical research enterprise.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.